JMP Securities analyst Jason Butler reiterated a Buy rating on Syros Pharmaceuticals (SYRS – Research Report) today and set a price target of $20.00. The company’s shares closed last Monday at $3.32, close to its 52-week low of $3.30.
According to TipRanks.com, Butler is a 2-star analyst with an average return of 0.5% and a 42.6% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Aquestive Therapeutics, and ACADIA Pharmaceuticals.
Syros Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $19.33, which is a 455.5% upside from current levels. In a report issued on January 3, Brookline Capital Markets also maintained a Buy rating on the stock with a $23.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $15.65 and a one-year low of $3.30. Currently, Syros Pharmaceuticals has an average volume of 339.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
Read More on SYRS:
